For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...
A Phase 2b/3, randomised, double-blind, placebo-controlled, parallel-group, multicentre protocol to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ...
Johnson & Johnson (J&J) has shared positive results from a late-stage study evaluating a subcutaneous (SC) version of Tremfya ...
Skyrizi (risankizumab) is the first IL-23-selective drug to be cleared for the inflammatory bowel disease – ahead of rivals like Johnson & Johnson's Tremfya (guselkumab), and Sun Pharma's Ilumya ...
and Tremfya (guselkumab), and Sun Pharma's Ilumya (tildrakizumab). In Crohn's, Skyrizi, Stelara, and Ilumya are already approved by the FDA, while Tremfya is under review, having been submitted to ...
Paul Goepfert, MD, Director for the Alabama Vaccine Research Clinic, stated: "I'm excited for the opportunity to follow-up on ...
After hours: 28 February at 7:58:44 pm GMT-5 ...
Severe cases may require treatment with powerful psoriasis medications, including: Trexall (methotrexate) Sandimmune (cyclosporine) Biologic drugs, including Enbrel (etanercept), Remicade (infliximab) ...
A 175% increase in human papilloma virus vaccination initiation was observed following the implementation of an office based, same-day vaccine program in a dermatology clinic. Vaccination rates for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback